Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuwellis (NUWE) Gains from Sales and Divestitures (2013 - 2019)

Nuwellis posted quarterly Gains from Sales and Divestitures of $3.0 for Q4 2019, down 75.0% year-on-year from $12.0 in Q4 2018, and down 75.0% on a QoQ basis from $12.0 in Q4 2018.

Nuwellis (NUWE) has 6 years of Gains from Sales and Divestitures data on file, last reported at $3.0 in Q4 2019.

  • For the quarter ending Q4 2019, Gains from Sales and Divestitures fell 75.0% year-over-year to $3.0; the trailing twelve-month figure through Dec 2019 stood at $3.0 (down 75.0% YoY), and the FY2019 full-year result was $3.0, down 75.0% from the prior year.
  • Gains from Sales and Divestitures for Q4 2019 stood at $3.0, down from $12.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $5704.0 in Q4 2015 and bottomed at $3.0 in Q4 2019.
  • The 5-year median for Gains from Sales and Divestitures is $29.0 (2017), against an average of $1273.4.
  • The widest annual swing landed in 2017, when Gains from Sales and Divestitures tumbled 95.32%; it then slumped 58.62% in 2018.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $5704.0 in 2015, then plunged by 89.15% to $619.0 in 2016, then sank by 95.32% to $29.0 in 2017, then tumbled by 58.62% to $12.0 in 2018, then sank by 75.0% to $3.0 in 2019.
  • The last three Gains from Sales and Divestitures figures came in at $3.0 (Q4 2019), $12.0 (Q4 2018), and $29.0 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Nuwellis 1.45 Mn -630,292.49 1.68 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 3.00
Dec 31, 2019 3.00
Dec 31, 2018 12.00
Dec 31, 2018 12.00
Dec 31, 2017 29.00
Dec 31, 2017 29.00
Dec 31, 2016 619.00
Dec 31, 2016 619.00
Dec 31, 2015 5,704.00
Dec 31, 2015 5,704.00
Dec 31, 2014 168,682.00
Dec 31, 2014 168,682.00
Dec 31, 2013 32,074.00
Dec 31, 2013 32,074.00